High levels of cystatin C predict the metabolic syndrome: the prospective Malmö Diet and Cancer Study.
(2013) In Journal of Internal Medicine 274(2). p.192-199- Abstract
- OBJECTIVE: Cystatin C is a novel marker of cardiovascular disease (CVD), however the underlying mechanisms remain unclear. Here, we prospectively investigated whether plasma levels of cystatin C predict new-onset metabolic syndrome (MetS) as well as long-term progression and incidence of the different components of the MetS. METHODS: Cystatin C was measured in 1502 individuals included in the Malmö Diet and Cancer cardiovascular cohort (mean age 56 years, 59% women) who were free from the MetS at baseline and subsequently underwent a follow-up examination after a median of 16 years. MetS was defined according to the NCEP-ATP-III guidelines. Logistic regression was used to adjust for covariates. MAIN OUTCOME MEASURES: MetS and long-term... (More)
- OBJECTIVE: Cystatin C is a novel marker of cardiovascular disease (CVD), however the underlying mechanisms remain unclear. Here, we prospectively investigated whether plasma levels of cystatin C predict new-onset metabolic syndrome (MetS) as well as long-term progression and incidence of the different components of the MetS. METHODS: Cystatin C was measured in 1502 individuals included in the Malmö Diet and Cancer cardiovascular cohort (mean age 56 years, 59% women) who were free from the MetS at baseline and subsequently underwent a follow-up examination after a median of 16 years. MetS was defined according to the NCEP-ATP-III guidelines. Logistic regression was used to adjust for covariates. MAIN OUTCOME MEASURES: MetS and long-term progression as well as incidence of the different components of the MetS. RESULTS: During follow-up, 428 subjects developed new-onset MetS. In age- and sex-adjusted analysis, compared to the lowest quartile of cystatin C, the odds ratios (95% confidence interval) for incident MetS in subjects with cystatin C levels in quartiles 2, 3 and 4 were 1.00 (0.71-1.40), 1.48 (1.06-2.07) and 1.91 (1.37-2.68), respectively, (P(trend) <0.001); this linear association remained significant even after full multivariate adjustment (P(trend) =0.041). Interestingly, in this fully adjusted model, long-term progression of abdominal obesity was the only component of the MetS significantly associated with increasing quartiles of baseline cystatin C levels (P(trend) =0.008). CONCLUSION: These findings suggest that cystatin C may adversely affect metabolic factors, particularly abdominal obesity, thus contributing to development of the MetS. Our results may help to explain the link between cystatin C and development of CVD. © 2013 The Association for the Publication of the Journal of Internal Medicine. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3559702
- author
- Magnusson, Martin LU ; Hedblad, Bo LU ; Engström, Gunnar LU ; Persson, Magnus LU ; Nilsson, Peter LU and Melander, Olle LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Internal Medicine
- volume
- 274
- issue
- 2
- pages
- 192 - 199
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000321665200011
- pmid:23414447
- scopus:84880326575
- pmid:23414447
- ISSN
- 1365-2796
- DOI
- 10.1111/joim.12051
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Cardio-vascular Epidemiology (013241610), Emergency medicine/Medicine/Surgery (013240200), Hypertension and Cardiovascular Disease (013242540), Internal Medicine Research Unit (013242520), Division of Health Economics and Forensic Medicine (Closed 2012) (013040050)
- id
- 2eb965f8-8c4c-4452-b18d-d550b2424cfa (old id 3559702)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23414447?dopt=Abstract
- date added to LUP
- 2016-04-01 10:46:32
- date last changed
- 2024-01-07 00:49:31
@article{2eb965f8-8c4c-4452-b18d-d550b2424cfa, abstract = {{OBJECTIVE: Cystatin C is a novel marker of cardiovascular disease (CVD), however the underlying mechanisms remain unclear. Here, we prospectively investigated whether plasma levels of cystatin C predict new-onset metabolic syndrome (MetS) as well as long-term progression and incidence of the different components of the MetS. METHODS: Cystatin C was measured in 1502 individuals included in the Malmö Diet and Cancer cardiovascular cohort (mean age 56 years, 59% women) who were free from the MetS at baseline and subsequently underwent a follow-up examination after a median of 16 years. MetS was defined according to the NCEP-ATP-III guidelines. Logistic regression was used to adjust for covariates. MAIN OUTCOME MEASURES: MetS and long-term progression as well as incidence of the different components of the MetS. RESULTS: During follow-up, 428 subjects developed new-onset MetS. In age- and sex-adjusted analysis, compared to the lowest quartile of cystatin C, the odds ratios (95% confidence interval) for incident MetS in subjects with cystatin C levels in quartiles 2, 3 and 4 were 1.00 (0.71-1.40), 1.48 (1.06-2.07) and 1.91 (1.37-2.68), respectively, (P(trend) <0.001); this linear association remained significant even after full multivariate adjustment (P(trend) =0.041). Interestingly, in this fully adjusted model, long-term progression of abdominal obesity was the only component of the MetS significantly associated with increasing quartiles of baseline cystatin C levels (P(trend) =0.008). CONCLUSION: These findings suggest that cystatin C may adversely affect metabolic factors, particularly abdominal obesity, thus contributing to development of the MetS. Our results may help to explain the link between cystatin C and development of CVD. © 2013 The Association for the Publication of the Journal of Internal Medicine.}}, author = {{Magnusson, Martin and Hedblad, Bo and Engström, Gunnar and Persson, Magnus and Nilsson, Peter and Melander, Olle}}, issn = {{1365-2796}}, language = {{eng}}, number = {{2}}, pages = {{192--199}}, publisher = {{Wiley-Blackwell}}, series = {{Journal of Internal Medicine}}, title = {{High levels of cystatin C predict the metabolic syndrome: the prospective Malmö Diet and Cancer Study.}}, url = {{http://dx.doi.org/10.1111/joim.12051}}, doi = {{10.1111/joim.12051}}, volume = {{274}}, year = {{2013}}, }